We are proud to announce that APICES has been acknowledged for its ongoing collaboration in the LOADH study, an Observational prospective study in Lung Cancer (NSCLC). This acknowledgement was highlighted in the Journal of Cancer Research and Clinical Oncology 2025.
APICES has contributed extensively to critical aspects throughout the trial, including start-up, coordination, project management, monitoring, medical monitoring, pharmacovigilance, data management, biostatistics, and medical writing activities.
This acknowledgment is a great motivation for the entire APICES team to continue the commitment we bring to every project we collaborate on. We sincerely thank Astrazeneca Spain and Dra. Irene Mangues-Bafalluy for giving us the opportunity to support the study as CRO and for including us acknowledgments. We also congratulate them and all investigators and patients on the LOADH Study progress and results.
The LOADH study aims to evaluate adherence to oral antineoplastic therapy (OAT) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and its potential relationship with several clinical outcomes.
For further information about the LOADH Study, please visit: LOADH STUDY
Get the latest clinical insights delivered to your feed or inbox!
Key Takeaways: First-in-human trials in the EU are governed by Regulation (EU) No 536/2014 and the EMA’s first-in-human guideline (EMEA/CHMP/SWP/28367/07 Rev 1). Sponsors must submit a complete Clinical Trial Application via the CTIS portal and obtain both Part I...
Key Takeaways: Phase I dose escalation design in the EU is governed by ICH E8(R1), EMA first-in-human guidance (EMA/CHMP/SWP/28367/07 Rev.1), and EU Clinical Trial Regulation 536/2014 via CTIS. The classical 3+3 design is increasingly replaced by model-based...
EU MDR clinical investigation requirements have fundamentally changed how Medtech sponsors plan and execute device studies in Europe. Regulation (EU) 2017/745 replaced the clinical investigation provisions of Directive 93/42/EEC (MDD) and introduced a more stringent, harmonised framework across all 27 EU member states. For sponsors running investigations in Spain, Germany, France, the Netherlands, or any other member state, understanding which pathway applies to their study is the single most consequential regulatory decision before CIP submission.
